Boehringer/Zealand’s Obesity Asset Succeeds In Phase II But Competition Is Fierce
Pivotal Plans In The Works
The partners’ dual GLP-1/GCGR agonist has achieved up to 14.9% weight loss in obese and overweight adults in a mid-stage trial but rival products Wegovy and Mounjaro will likely dominate the space according to analysts.
